AHPA Rewrites NDI Guidance, Argues FDA Proposes Premarket Approval For Supplements
This article was originally published in The Tan Sheet
Executive Summary
The NDI draft guidance “seeks to erect extra-legal barriers to market entry” and change supplement regulation “from the notification process described under law to an FDA approval process,” AHPA argues, joining other trade groups urging FDA to withdraw the guidance